Dynavax Technologies Corp. (DVAX) announced Monday that it received a Complete Response Letter or CRL from the U.S. Food and Drug Administration regarding its Biologic License Application or BLA for HEPLISAV, an investigational adult hepatitis B vaccine.
In the CRL, the FDA specified that the indication in adults 18-70 years of age cannot be approved without further evaluation of safety in this broad age group. The FDA also continues to express concern that novel adjuvants may cause rare autoimmune events. However, the Agency indicated its willingness to continue discussions regarding a more restricted use of HEPLISAV.
The company added that it plans to discuss the CRL with the FDA to identify the most expeditious path to approval for HEPLISAV, particularly in adults who may receive the greatest benefit from HEPLISAV.
In addition, the FDA requested additional data from Dynavax's process validation program and clarifying information on the manufacturing controls and facilities related to the assurance of the quality of the commercial product.
The company believes it can provide the information but the exact timeframe for its response cannot be determined until it has met with the Agency.
The company also plans to meet with the FDA to discuss the steps necessary for potential approval of HEPLISAV and currently believes the meeting can take place within 6 weeks.
Dynavax's BLA was accepted for review by the FDA in June 2012. On November 15, 2012, the FDA's Vaccines and Related Biological Products Advisory Committee (Committee) voted 8 to 5 with 1 abstention that there was insufficient data to adequately support the safety of HEPLISAV, although the Committee voted 13 to 1 that HEPLISAV data adequately demonstrated immunogenicity.
The company noted that its Marketing Authorization Application continues to be under review in Europe.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org